Polyrizon (PLRZ) Enrolls First Patient in NASARIX Allergy Spray Trial

Polyrizon Ltd. (PLRZ) said Tuesday it enrolled the first patient in a clinical study of NASARIX, its intranasal treatment candidate for seasonal allergic rhinitis. The Israel-based clinical-stage biotechnology company did not disclose the trial's size, phase or expected data timeline. Seasonal allergic rhinitis affects an estimated 10% to 30% of adults worldwide, according to the World Allergy Organization, creating a sizable market for new intranasal therapies. The announcement is an early-stage clinical milestone and provides no efficacy or safety data. Shares of PLRZ trade on Nasdaq.